Home>Topics>Stocks>Orexigen Therapeutics

Orexigen Therapeutics OREX

  1. All
  2. Commentary
  3. Headlines
    1. Belviq Sales Recover From Holiday Dip

      Headlines

      Sun, 21 Sep 2014

      By Spencer Osborne : Arena Pharmaceuticals' (NASDAQ: ARNA ) anti-obesity pill Belviq saw a full recovery from a holiday dip in sales last week with a 15% gain this week. Sales in the most recent week demonstrated a full recovery plus a modest increase above the pre-holiday sales levels. The rise ...

    2. It Takes Less Than 15 Minutes To Buy VVUS Shares!

      Headlines

      Fri, 19 Sep 2014

      in excess of a billion dollars per year. Qsymia will compete with Belviq by Arena (NASDAQ: ARNA ). Orexigen's (NASDAQ: OREX ) drug was recently approved by the FDA, with the requirement for more safety trials like Qysimia. Discussion of the earnings

    3. Orexigen Therapeutics ( OREX ) Presents at Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

      Headlines

      Thu, 18 Sep 2014

      By SA Transcripts : Orexigen Therapeutics , Inc. (NASDAQ: OREX ) Bank of America Merrill Lynch Global Healthcare Conference September 18, 2014 11:10 AM ET Executives Mark Booth - CCO McDavid

    4. Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away

      Headlines

      Tue, 16 Sep 2014

      By Long Term Bio : Orexigen Therapeutics (NASDAQ: OREX ) received FDA approval for their obesity drug Contrave ..... to give to patients to help reduce their weight. Orexigen Therapeutics has been struggling to receive FDA approval for Contrave

    5. Orexigen Falls After Approval - Why?

      Headlines

      Mon, 15 Sep 2014

      By Spencer Osborne : Orexigen (NASDAQ: OREX ) shares have tumbled upon FDA approval of the anti-obesity drug Contrave. This type of market reaction may not be what some

    6. Arena And Vivus Ruined The FDA Approval Run Up For Orexigen

      Headlines

      Sat, 13 Sep 2014

      By R.S. Analytics : Orexigen's (NASDAQ: OREX ) obesity drug, Contrave, finally received FDA approval last Thursday. Unfortunately for Orexigen longs, Arena Pharmaceutical

    7. Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead

      Headlines

      Fri, 12 Sep 2014

      By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different dose (3mg) form of liaglutide that would be injected once a day for patienmts seeking to treat obesity. The FDA's ...

    8. Orexigen: Poised To Grab A Large Part Of The Weight Loss Market

      Headlines

      Fri, 12 Sep 2014

      By Alexander Maxwell : Orexigen Therapeutics (NASDAQ: OREX ) investors were finally rewarded for their patience, after obtaining FDA approval for Orexigen's weight-loss drug Contrave

    9. Belviq Advertising Sees Major Shift

      Headlines

      Fri, 12 Sep 2014

      Labor Day weekend and preempted the announcement regarding the approval of a competing drug, Contrave, from Orexigen (NASDAQ: OREX ). During the week of September 1st through September 7th Belviq was advertised just 136 times but was in time slots that had

    10. A New Nifty Fifty States Stock Index

      Headlines

      Fri, 12 Sep 2014

      By Fredrik Arnold : Weary of Wall Street Wizard Weights? Are you sick and tired of the same old dreary record-breaking numbers being reported for the DowJones30; S&P500; NASDAQ100; RUSSELL3000; BARRON400; ValueLineXYZ; Etc.; Etc.? Here's the cure. It's a patriotic collection of stocks selected by

    « Prev12345Next »
    Content Partners